Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

Author(s): Hope S. Rugo, MD1; Aditya Bardia, MD, MPH2; Frederik Marmé, MD, PhD3; Javier Cortes, MD, PhD4,5; Peter Schmid, MD, PhD6; Delphine Loirat, MD, PhD7; Olivier Trédan, MD, PhD8; Eva Ciruelos, MD, PhD9; Florence Dalenc, MD, PhD10; Patricia Gómez Pardo, MD11; Komal L. Jhaveri, MD12; Rosemary Delaney, MPH13; Olivia Fu, MD14; Lanjia Lin, PhD15; Wendy Verret, PhD13; and Sara M. Tolaney, MD, MPH16
Source: DOI: 10.1200/JCO.22.01002 Journal of Clinical Oncology 40, no. 29 (October 10, 2022) 3365-3376
Maem Hussein MD

Dr. Maen Hussein's Thoughts

Another option for HR+ /HER-2 negative pts who failed hormonal therapies, caution to toxicity though esp neutropenia and diarrhea, no OS data yet, will be interesting to know if it worth the adverse events at this stage of disease.



Hormone receptor–positive (HR+) human epidermal growth factor receptor 2–negative (HER2–) endocrine-resistant metastatic breast cancer is treated with sequential single-agent chemotherapy with poor outcomes. Sacituzumab govitecan (SG) is a first-in-class antibody-drug conjugate with an SN-38 payload targeting trophoblast cell-surface antigen 2, an epithelial antigen expressed in breast cancer.


In this global, randomized, phase III study, SG was compared with physician’s choice chemotherapy (eribulin, vinorelbine, capecitabine, or gemcitabine) in endocrine-resistant, chemotherapy-treated HR+/HER2– locally recurrent inoperable or metastatic breast cancer. The primary end point was progression-free survival (PFS) by blinded independent central review.


Patients were randomly assigned to receive SG (n = 272) or chemotherapy (n = 271). The median age was 56 years, 95% had visceral metastases, and 99% had a prior cyclin-dependent kinase 4/6 inhibitor, with three median lines of chemotherapy for advanced disease. Primary end point was met with a 34% reduction in risk of progression or death (hazard ratio, 0.66 [95% CI, 0.53 to 0.83; P = .0003]). The median PFS was 5.5 months (95% CI, 4.2 to 7.0) with SG and 4.0 months (95% CI, 3.1 to 4.4) with chemotherapy; the PFS at 6 and 12 months was 46% (95% CI, 39 to 53) v 30% (95% CI, 24 to 37) and 21% (95% CI, 15 to 28) v 7% (95% CI, 3 to 14), respectively. Median overall survival (first planned interim analysis) was not yet mature (hazard ratio, 0.84; P = .14). Key grade ≥ 3 treatment-related adverse events (SG v chemotherapy) were neutropenia (51% v 38%) and diarrhea (9% v 1%).


SG demonstrated statistically significant PFS benefit over chemotherapy, with a manageable safety profile in patients with heavily pretreated, endocrine-resistant HR+/HER2– advanced breast cancer and limited treatment options.

Author Affiliations

1Department of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; 2Medical Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; 3Medical Faculty Mannheim, Heidelberg University, University Hospital Mannheim, Heidelberg, Germany; 4Medical Oncology Department, International Breast Cancer Center, Pangaea Oncology, Quironsalud Group, Madrid and Barcelona, Spain; 5Faculty of Biomedical and Health Sciences, Department of Medicine, Universidad Europea de Madrid, Madrid, Spain; 6Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; 7Medical Oncology Department and D3i, Institut Curie, Paris, France; 8Medical Oncology Department, Centre Léon Bérard, Lyon, France; 9Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain; 10Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France; 11Hospital Universitari Vall D’Hebron, Barcelona, Spain; 12Memorial Sloan-Kettering Cancer Center, New York, NY; 13Department of Clinical Development, Gilead Sciences Inc, Foster City, CA; 14Department of Global Patient Safety, Gilead Sciences Inc, Foster City, CA; 15Department of Biostatistics, Gilead Sciences Inc, Foster City, CA; 16Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

Leave a Comment

Your email address will not be published. Required fields are marked *

Related Articles

Final results of RIGHT Choice: Ribociclib plus endocrine therapy vs combination chemotherapy in premenopausal women with clinically aggressive HR+/HER2− advanced breast cancer

Nicely done study comparing Ribociclib + ET vs chemotherapy in premenopausal high-risk HR+, HER2-neg patients felt to be high risk. Results showed better efficacy (PFS), tolerability and similar response rates. Of note, >80% of patients had visceral disease or were felt to be rapid progressors. Anti-hormone-based therapy remains king in the HR+ setting.

Read More »

PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor–Negative Metastatic Breast Cancer

Findings from the PACE study show that the addition of Palbociclib to Fulvestrant was not better than Fulvestrant alone, and the addition of Avelumab to Fulvestrant improved and nearly doubled the PFS. This is compelling and should be studied further for our patients with HR+ HER2- MBC.

Read More »

Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial

This is a study showing tumor agnostic activity of trastuzumab deruxtecan (T-DXd) with an all-comer overall response rate (ORR) of 37.1%, duration of response (DOR) of 11.3 months and an overall survival (OS) of 13.4 months in an otherwise heavily pre-treated group. Those with IHC-3+ derived larger benefit than 2+. Patients with ERBB2 mutations who had no expression of HER2 were excluded from the trial.

Read More »